MG
KDNY

Michael Gelband’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Michael Gelband’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-128,955
Closed -$3.38M – 2227
2022
Q4 		$3.38M Sell
128,955
-41,701
-24% -$924K 0.05% 463
2022
Q3 		$3.35M Buy
170,656
+10,178
+6% +$204K 0.04% 550
2022
Q2 		$2.81M Buy
+160,478
New +$2.52M 0.03% 642
2021
Q2 		– Sell
-13,852
Closed -$215K – 2955
2021
Q1 		$215K Buy
+13,852
New +$226K ﹤0.01% 1843

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Michael Gelband's KDNY Position: Q1 2023 in Review

Michael Gelband sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 128,955 shares — an estimated $3.38M sold.

Michael Gelband first reported a position in KDNY in Q1 2021 and held it in 4 quarters. The position peaked at $3.38M in Q4 2022. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

  • Michael Gelband reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Michael Gelband sold 128,955 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.38M.
  • Michael Gelband first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Michael Gelband's Chinook Therapeutics, Inc. Common Stock position peaked at $3.38M in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.